We are live on ! Find out more
FBRX icon

Forte Biosciences

58 hedge funds and large institutions have $4.38M invested in Forte Biosciences in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 14 increasing their positions, 20 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more call options, than puts

Call options by funds: $363K | Put options by funds: $156K

0.02% less ownership

Funds ownership: 0.09%0.07% (-0.02%)

22% less funds holding

Funds holding: 7458 (-16)

30% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 20

71% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 21

92% less capital invested

Capital invested by funds: $56.4M → $4.38M (-$52M)

Holders
58
Holders Change
-16
Holders Change %
-21.62%
% of All Funds
1.27%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
6
Increased
14
Reduced
20
Closed
21
Calls
$363K
Puts
$156K
Net Calls
+$207K
Net Calls Change
+$146K
Name Holding Trade Value Shares
Change
Change in
Stake
Simplex Trading
51
Simplex Trading
Illinois
$2K -$10.6K -7 -41%
Carson Wealth (CWM LLC)
52
Carson Wealth (CWM LLC)
Nebraska
$2K
Legal & General Group
53
Legal & General Group
United Kingdom
$2K
LWCFA
54
Loring Wolcott & Coolidge Fiduciary Advisors
Massachusetts
$2K
AIP
55
Ameritas Investment Partners
Nebraska
$1K
Bank of Montreal
56
Bank of Montreal
Ontario, Canada
$1K
Federated Hermes
57
Federated Hermes
Pennsylvania
$1K
PGAM
58
Princeton Global Asset Management
New Jersey
$1K +$1.52K +1 New
SAM
59
Sectoral Asset Management
Quebec, Canada
-$4.48M -1,787 Closed
FCMI
60
Foresite Capital Management III
California
-$3.79M -1,515 Closed
T. Rowe Price Associates
61
T. Rowe Price Associates
Maryland
-$3.35M -1,339 Closed
6CM
62
683 Capital Management
New York
-$2.5M -1,000 Closed
RCMNY
63
Rubric Capital Management (New York)
New York
-$723K -289 Closed
Jacobs Levy Equity Management
64
Jacobs Levy Equity Management
New Jersey
-$416K -166 Closed
CBT
65
Capital Bank & Trust
California
-$334K -133 Closed
SSA
66
Schonfeld Strategic Advisors
New York
-$267K -107 Closed
GIM
67
Granahan Investment Management
Massachusetts
-$264K -105 Closed
Stifel Financial
68
Stifel Financial
Missouri
-$245K -98 Closed
TD Asset Management
69
TD Asset Management
Ontario, Canada
-$175K -70 Closed
State of Wisconsin Investment Board
70
State of Wisconsin Investment Board
Wisconsin
-$164K -66 Closed
ACA
71
Apis Capital Advisors
New York
-$134K -53 Closed
DY
72
Dowling & Yahnke
California
-$114K -46 Closed
Manulife (Manufacturers Life Insurance)
73
Manulife (Manufacturers Life Insurance)
Ontario, Canada
-$106K -42 Closed
RCM
74
Requisite Capital Management
Texas
-$80K -32 Closed
AQR Capital Management
75
AQR Capital Management
Connecticut
-$74K -30 Closed

FBRX Hedge Fund Activity: Q3 2019 in Review

58 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Forte Biosciences (FBRX) for Q3 2019, worth a combined $4.38M — down 92% from $56.4M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of FBRX and 6 opened new positions — a net loss of 15 holders — while 20 trimmed existing stakes and 14 added.

The largest buyer was ISZO Capital Management, opening a new position worth an estimated $2.29M. The largest seller was Sectoral Asset Management, exiting entirely with an estimated $4.48M sold.

  • 58 institutional investors held Forte Biosciences (FBRX) as of Q3 2019, down from 74 in Q2 2019.
  • Funds reported $4.38M of Forte Biosciences stock for Q3 2019, down 92% quarter-over-quarter.
  • 6 funds opened new Forte Biosciences positions in Q3 2019 and 21 closed out, a net change of -15 holders.
  • The largest Forte Biosciences buyer in Q3 2019 was ISZO Capital Management, an estimated $2.29M added.
  • The largest Forte Biosciences seller in Q3 2019 was Sectoral Asset Management, an estimated $4.48M sold.

Based on aggregated 13F filings for Q3 2019.